About Onkologic
Onkologic is a company based in Farmington (United States) founded in 2021 by Rachit Ohri. Onkologic has raised $305 thousand across 1 funding round. Onkologic offers products and services including Enable-NKâ„¢ Duo, Enable-NKâ„¢ Grow, and Enable-NKâ„¢ Activate. Onkologic operates in a competitive market with competitors including Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
- Headquarter Farmington, United States
- Founders Rachit Ohri
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website onkologic.com
- Social LinkedIn
- Legal Name Onkologic, Inc.
- Total Equity Funding$305K (USD)
in 1 rounds
- Latest Funding Round$305K (USD), Seed
Apr 2022
Products & Services of Onkologic
Onkologic offers a comprehensive portfolio of products and services, including Enable-NK™ Duo, Enable-NK™ Grow, and Enable-NK™ Activate.
Formulation for growing and activating Natural Killer cells in therapies.
Media component to optimize NK cell growth and reduce exhaustion.
Media for enhancing NK cell performance in immunotherapies.
Funding Insights of Onkologic
Onkologic has successfully raised a total of $305K through 1 strategic funding round. The most recent funding activity was a Seed round of $305 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $305,000
- Total Rounds 1
- Last Round Seed — $305,000
- First Round $305,000
(Apr 2022)
All 1 funding rounds of Onkologic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $305,000 | Seed | – | – | – |
People of Onkologic
1 people are tracked at Onkologic (1 in leadership).
| Name | Role | Group |
|---|---|---|
Rachit Ohri | Founder & CEO | Leadership |
Complete people profiles for Onkologic
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Onkologic
2 dated milestones of Onkologic across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Onkologic is founded.
- Funding First funding round of $305K.
Competitors of Onkologic
Onkologic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| multus.bio | 2019 | London, United Kingdom | $9.3M | 8 | Provider of lab-grown meat alternatives | |
| metatissue.com | 2018 | Ilhavo, Portugal | – | – | Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications | |
| nu-tekbiosciences.com | 2008 | Minnetonka, United States | – | – | Develops innovative animal-free peptones and cell culture media for pharmaceutical use. | |
| kohjin-bio.jp | 1981 | Sakado, Japan | – | – | Tissue culture media provided for regenerative medicine and immunotherapy research. | |
| sarvoshadhi.com | 2017 | Kolhapur, India | – | – | Customized cell culture media for biotechnology are developed. | |
| metaboliq.ca | 2022 | Canada | – | – | Developer of cell culture medium for pharmaceutical screening and personalized medicine | |
| alt-biotech.com | 2023 | Evry Courcouronnes, France | – | – | Delivers comprehensive cell-culture solutions for producing non-therapeutic recombinant proteins. | |
| cet.bio | 2000 | Coralville, United States | $45,000 | – | Cell lines and stem cell products are supplied to researchers. |
Detailed competitors of Onkologic
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Onkologic
10 companies that operate in the same segment as Onkologic (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Onkologic
Onkologic was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Onkologic is headquartered in Farmington, United States.
Rachit Ohri is the current CEO of Onkologic. They have also founded this company.
Onkologic is a funded company, having raised a total of $305K across 1 funding round to date. The company's 1st funding round was a Seed of $305K, raised on Apr 2022.
Onkologic was founded in 2021 and is based in Farmington, United States. Operations focus on the biotechnology sector, where reformulated NK cell media products are provided to enhance the efficacy and potency of NK cellular immunotherapies against cancer. Formulations for CD56 immune cells, including gamma-delta T cells, are also offered to support related cell therapy applications.
Onkologic's top competitors include Multus, Cellular Engineering Technologies and Metatissue.
Onkologic offers Enable-NKâ„¢ Duo, Enable-NKâ„¢ Grow, and Enable-NKâ„¢ Activate.
Onkologic operates through Onkologic, Inc..